DE69713367D1 - Verfahren zur herstellung einer pharmazeutischen zusammensetzung mit veränderter wirkstoffsfreisetzung, enthaltend eine matrix - Google Patents

Verfahren zur herstellung einer pharmazeutischen zusammensetzung mit veränderter wirkstoffsfreisetzung, enthaltend eine matrix

Info

Publication number
DE69713367D1
DE69713367D1 DE69713367T DE69713367T DE69713367D1 DE 69713367 D1 DE69713367 D1 DE 69713367D1 DE 69713367 T DE69713367 T DE 69713367T DE 69713367 T DE69713367 T DE 69713367T DE 69713367 D1 DE69713367 D1 DE 69713367D1
Authority
DE
Germany
Prior art keywords
matrix
producing
pharmaceutical composition
active substance
modified active
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69713367T
Other languages
English (en)
Other versions
DE69713367T2 (de
Inventor
Nabil Farah
Philippe Barthelemy
Joseph Joachim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GATTEFOSSE HOLDING, SAINT PRIEST, FR
Original Assignee
Gattefosse SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gattefosse SA filed Critical Gattefosse SA
Publication of DE69713367D1 publication Critical patent/DE69713367D1/de
Application granted granted Critical
Publication of DE69713367T2 publication Critical patent/DE69713367T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
DE69713367T 1996-10-01 1997-09-29 Verfahren zur herstellung einer pharmazeutischen zusammensetzung mit veränderter wirkstoffsfreisetzung, enthaltend eine matrix Expired - Lifetime DE69713367T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9612156A FR2753904B1 (fr) 1996-10-01 1996-10-01 Composition pharmaceutique a liberation modifiee de principe actif, comportant une matrice, et procede de fabrication
PCT/FR1997/001710 WO1998014176A1 (fr) 1996-10-01 1997-09-29 Procede de fabrication d'une composition pharmaceutique a liberation modifiee de principe actif, comportant une matrice

Publications (2)

Publication Number Publication Date
DE69713367D1 true DE69713367D1 (de) 2002-07-18
DE69713367T2 DE69713367T2 (de) 2003-03-06

Family

ID=9496393

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69713367T Expired - Lifetime DE69713367T2 (de) 1996-10-01 1997-09-29 Verfahren zur herstellung einer pharmazeutischen zusammensetzung mit veränderter wirkstoffsfreisetzung, enthaltend eine matrix

Country Status (9)

Country Link
US (1) US6194005B1 (de)
EP (1) EP0935459B1 (de)
JP (1) JP2001501218A (de)
KR (1) KR20000048761A (de)
AU (1) AU4464897A (de)
DE (1) DE69713367T2 (de)
ES (1) ES2176785T3 (de)
FR (1) FR2753904B1 (de)
WO (1) WO1998014176A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2779651B1 (fr) * 1998-06-16 2001-04-20 Gattefosse Ets Sa Procede pour la fabrication de comprimes a liberation prolongee de principe(s) actif(s) presentant une cinetique de dissolution d'ordre zero
FR2784895B1 (fr) * 1998-10-23 2004-12-17 Gattefosse Ets Sa Comprime a croquer a gout masque et liberation immediate du principe actif et procede de fabrication
KR101476574B1 (ko) 1999-10-29 2014-12-24 유로-셀티크 소시에떼 아노뉨 서방성 하이드로코돈 제형
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
SK285128B6 (sk) * 1999-12-28 2006-07-07 Zentiva, A. S. Liečivý prípravok s riadeným uvoľňovaním obsahujúci tramadol hydrochlorid a spôsob jeho prípravy
MXPA03003895A (es) 2000-10-30 2003-07-28 Euro Celtique Sa Formulaciones de hidrocodona de liberacion controlada.
FR2822381B1 (fr) * 2001-03-20 2004-10-22 Bio Obtention Sc Extrait de cucumis melo enrobe et/ou microencapsule dans un agent liposoluble a base de matiere grasse
SK286107B6 (sk) * 2002-04-12 2008-03-05 Zentiva, A. S. Analgeticky účinný perorálny liečivý prípravok s kontrolovaným uvoľňovaním opioidnej účinnej látky a spôsob jeho prípravy
US20040043070A1 (en) * 2002-05-14 2004-03-04 Ayres James W. Hot melt coating by direct blending and coated substrates
US20030235613A1 (en) * 2002-06-19 2003-12-25 Cts Chemical Industries Ltd. Popping oral administration form
US20070141071A1 (en) * 2003-05-14 2007-06-21 Oregon State University Hot melt coating by direct blending and coated substrates
US7364755B2 (en) * 2003-07-07 2008-04-29 Synthon Ip Inc. Modified calcium phosphate excipient
US20080069891A1 (en) * 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
EP1972336A1 (de) * 2007-03-19 2008-09-24 LEK Pharmaceuticals D.D. Heißschmelz-Mikropellets
DE102007026550A1 (de) 2007-06-08 2008-12-11 Bayer Healthcare Ag Extrudate mit verbesserter Geschmacksmaskierung
US20090004285A1 (en) * 2007-06-29 2009-01-01 Liangping Yu Stable non-disintegrating dosage forms and method of making same
FR2959130A1 (fr) * 2010-04-21 2011-10-28 Sanofi Aventis Procede de preparation de compositions pharmaceutiques destinees a l'administration par voie orale comprenant un ou plusieurs principes actifs et les compositions les comprenant.
US8927025B2 (en) 2010-05-11 2015-01-06 Cima Labs Inc. Alcohol-resistant metoprolol-containing extended-release oral dosage forms
US11071805B2 (en) 2013-04-22 2021-07-27 Sealantium Medical Ltd. Fibrinogen-based tissue adhesive patches
WO2017068572A1 (en) 2015-10-19 2017-04-27 Sealantium Medical Ltd Improved fibrinogen-based tissue adhesive patch
US11471556B2 (en) 2015-10-19 2022-10-18 Sealantium Medical Ltd. Fibrinogen-based tissue adhesive patch
US20180207328A1 (en) * 2017-01-22 2018-07-26 Kamalesh K. Rao Implantable Compositions for Pain Management
JP2021509111A (ja) * 2017-12-27 2021-03-18 グラール ソシエタ ア レスポンサビリタ リミタータ 遅延放出固体配合物の調製のための方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4129666A (en) 1977-04-29 1978-12-12 Walter Wizerkaniuk Method of providing pellets with a water insoluble coating using a melt
FR2573307B1 (fr) * 1984-11-22 1988-06-10 Virbac Ctre Rech Biolog Implants anabolisants a liberation prolongee
EP0421581A1 (de) * 1989-10-03 1991-04-10 Warner-Lambert Company Kaubare sprühgetrocknete spheroide Mikrokapseln, wachsüberzogene Mikrokapseln und Verfahren zu ihrer Herstellung
DE4001622A1 (de) * 1990-01-20 1991-07-25 Thomae Gmbh Dr K Orale arzneimittelformen von pimobendan
JPH03232814A (ja) * 1990-02-08 1991-10-16 Shin Etsu Chem Co Ltd 徐放性錠剤の製造方法
JP3078859B2 (ja) * 1990-02-23 2000-08-21 武田薬品工業株式会社 安定な放出制御性製剤用コーティング剤
JP2553258B2 (ja) * 1991-05-20 1996-11-13 三菱化学株式会社 ワックス被覆製剤の製造方法
GB9224855D0 (en) 1992-11-27 1993-01-13 Smithkline Beecham Plc Pharmaceutical compositions
SE9301112D0 (sv) * 1993-04-02 1993-04-02 Orion-Yhtymae Oy A new composition
IL109770A0 (en) * 1993-05-29 1994-11-28 Smithkline Beecham Corp Thermal infusion process for preparing controlled release solid dosage forms of medicaments for oral administration and controlled release solid dosage forms of medicaments prepared thereby
EP0744941B1 (de) * 1994-02-16 2003-06-04 Abbott Laboratories Verfahren zur herstellung feinteiliger pharmazeutischer formulierungen

Also Published As

Publication number Publication date
US6194005B1 (en) 2001-02-27
JP2001501218A (ja) 2001-01-30
WO1998014176A1 (fr) 1998-04-09
FR2753904A1 (fr) 1998-04-03
AU4464897A (en) 1998-04-24
EP0935459B1 (de) 2002-06-12
KR20000048761A (ko) 2000-07-25
FR2753904B1 (fr) 1998-10-30
ES2176785T3 (es) 2002-12-01
EP0935459A1 (de) 1999-08-18
DE69713367T2 (de) 2003-03-06

Similar Documents

Publication Publication Date Title
DE69713367D1 (de) Verfahren zur herstellung einer pharmazeutischen zusammensetzung mit veränderter wirkstoffsfreisetzung, enthaltend eine matrix
DE790240T1 (de) Phenol-Derivate mit pharmazeutischer Aktivität und Verfahren zu ihrer Herstellung
ATA125988A (de) Pharmazeutische cefuroximaxetil-zusammensetzung und verfahren zu ihrer herstellung
DE58904479D1 (de) Pharmazeutische zubereitung sowie verfahren zu ihrer herstellung.
DE69811735T2 (de) Heterocyclische verbindungen zur hemmung der magensäureproduktion, verfahren zu ihrer herstellung und pharmazeutische zubereitungen davon
ATE234291T1 (de) Metallproteinasehemmer, diesen enthaltende pharmazeutische zusammensetzung und dessen pharmazeutische verwendung und verfahren zu ihrer herstellung
ATE307576T1 (de) Fenofibrathaltige arzneizusammensetzung mit erhöhter bioverfügbarkeit und verfahren zu deren herstellung
DE60043701D1 (de) Verfahren zur herstellung von calendulasäure, einer fettsäure mit delta-8,10,12 konjugierten doppelbindungen und dimorphekolinsäure, einer fettsäure mit einer 9-hydroxyl-gruppe und delta-10,12 konjugierten doppelbindungen
DE3780226D1 (de) Neue pharmazeutische praeparate zur topischen applikation, verfahren zu ihrer herstellung und ihre verwendung.
DE69010919D1 (de) Dentale abdrucklöffel sowie verfahren zur herstellung.
DE69411604T2 (de) Wirkstoffzusammensetzung und Verfahren zu ihrer Herstellung
DE69004764T2 (de) Harzzusammensetzung und Verfahren zu ihrer Herstellung.
DE68924533D1 (de) Knochenwachstumsmatrix und verfahren zu ihrer herstellung.
DE69005987T2 (de) Dichtung, Vorrichtung und Verfahren zur ihrer Herstellung.
DE59608606D1 (de) Cyclosprorin(e) enthaltende pharmazeutische zubereitung zur oralen applikation und verfahren zu ihrer herstellung
DE69800805T2 (de) Verfahren zur herstellung chiraler 3,4-epoxybuttersäure und ihrer salze
DE68905625T2 (de) Verfahren zur herstellung aromatischer hydroxycarbonsaeuren.
DE3888036D1 (de) Optisch aktive Verbindung, Verfahren zur ihrer Herstellung und sie enthaltende flüssigkristalline Zusammensetzung.
ATE143010T1 (de) Pyridazin-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen
DE69012650D1 (de) Piperidinderivat, Verfahren zur Herstellung davon und dieses enthaltende pharmazeutische Zusammensetzung.
DE69828191D1 (de) Verfahren zur herstellung von 2,6-dialkylnaphthalin
DE59310184D1 (de) Verfahren zur herstellung dünnflüssiger, lagerstabiler amphotenside
DE69026906D1 (de) Arylpyrrol enthaltende insekticidale, acaricidale und nematicidale Mittel sowie Verfahren zu ihrer Herstellung
DE69715667D1 (de) Verfahren zur herstellung einer multipartikulären pharmazeutischen form mitgesteuerter etappenweiser freisetzung
DE68905837T2 (de) 2-(alkyl-cyclohexyl)-1-propanol, verfahren zu dessen herstellung und ihn enthaltende riechstoffzusammensetzung.

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: GATTEFOSSE HOLDING, SAINT PRIEST, FR

8364 No opposition during term of opposition